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Abstract: Congenital heart defects (CHD) are developmental malformations affecting the heart and
the great vessels. Early heart development requires temporally regulated crosstalk between multiple
cell types, signaling pathways, and mechanical forces of early blood flow. While both genetic and en-
vironmental factors have been recognized to be involved, identifying causal genes in non-syndromic
CHD has been difficult. While variants following Mendelian inheritance have been identified by
linkage analysis in a few families with multiple affected members, the inheritance pattern in most
familial cases is complex, with reduced penetrance and variable expressivity. Furthermore, most
non-syndromic CHD are sporadic. Improved sequencing technologies and large biobank collections
have enabled genome-wide association studies (GWAS) in non-syndromic CHD. The ability to gener-
ate human to create human induced pluripotent stem cells (hiPSC) and further differentiate them to
organotypic cells enables further exploration of genotype–phenotype correlations in patient-derived
cells. Here we review how these technologies can be used in unraveling the genetics and molecular
mechanisms of heart development.
Keywords: congenital heart disease; genetics; genome-wide association studies; massively parallel
sequencing; human induced pluripotent stem cells
1. Introduction
Congenital heart defects (CHD) are the most common form of congenital malforma-
tions, affecting 0.8–1% of the population [1]. CHD may occur as an element of a syndrome
or as an isolated condition. Non-syndromic CHD (nsCHD) can be familial or sporadic. In
familial forms, nsCHD is characterized by incomplete penetrance and variable expressiv-
ity [2,3], and an inherited etiology can be identified in approximately one-third to half of
the familial cases [4–6]. By contrast, in most sporadic nsCHD cases, a genetic etiology has
not been identified with only ca. 10% representing de novo genetic variants and 3–10%
copy number variation [7,8]. It appears that nsCHD is often oligogenic, with two or more
predisposing genetic variants contributing to disease [9,10]. An interesting recent study
using Mendelian Randomization (MR) proposed a new heritable form of risk for CHD
originating from inherited extremes in the size of developing cardiovascular anatomy,
where inheritance of a smaller diameter of the ascending aorta corresponded to an increase
in risk for left ventricular outflow tract (LVOT) CHD [11]. In addition to genetic variations,
nsCHD risk factors include epigenetic changes [12] and adverse environmental stimuli,
such as maternal glycemic dysregulation, obesity, and certain medications and infections
during pregnancy [13–16].
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New technologies have paved the way to an improved understanding of CHD. Next-
generation sequencing and genome-wide association studies (GWAS) have expanded
our understanding of the etiological factors of CHD. Patient-derived human-induced
pluripotent stem cells (hiPSCs) provide an excellent tool for disease modeling. Genetic
factors have also been identified to impact disease course [17–19], expanding the clinical
significance of understanding their impact on CHD. In this review, we discuss how these
methods can be used to identify new genes and signaling pathways underlying CHD and
to explore how genetic variants impact disease prognosis and outcome of care.
2. Identification of Causative Genes by Linkage Analysis and
Chromosomal Microarray
The first genes associated with CHD were identified in 1998 by linkage analysis in
families with multiple affected members. Pathogenic dominant NKX2-5 variants were
identified in four families with a history of secundum atrioventricular septal defects (ASD),
ventricular septal defects (VSD), subvalvular aortic stenosis (SVAS), Tetralogy of Fallot
(TOF) with pulmonary atresia (PA), and atrioventricular conduction abnormalities [3].
GATA4 was identified as a causal dominant variant in a family with recurring septal defects
and insufficiency of cardiac valves [20]. NOTCH1 was identified by linkage analysis to
cause left ventricular outflow tract obstruction (LVOTO) defects and other CHD [21]. In
addition to nsCHD, TBX5 and TBX20 were shown by this technique to cause CHD with
malformations of other organ systems [22,23].
During the early 2000s, the development of array comparative genomic hybridization
enabled high-resolution genome-wide screening for copy number variants (CNVs) [24].
Pathogenic CNVs have been identified in ca. 10% of nsCHDs, and an excess burden rate of
rare CNVs in nsCHD patients compared with healthy controls has been noted in several
studies [19,25–27]. The observation that CNVs are predominantly associated with CHD
with extracardiac anomalies [28,29] may be due to the altered function of multiple genes by
the CNV. Besides influencing the transcription of the genes localized within the CNV, CNVs
can regulate the expression of target genes at a distance [30]. Chromosomal microarray is
usually the first-line genetic test done in the clinical setting to identify CNVs in CHD with
extracardiac anomalies and in individuals with conotruncal defects or type A interruption
of the aortic arch as these can be the only early manifestation of 22q11-deletion syndrome.
3. Next-Generation Sequencing as a Tool for CHD
The majority of known large effect variants contributing to genetic conditions reside in
coding DNA. Therefore, selectively sequencing the exons of protein-coding genes, whole-
exome sequencing (WES), has become a prudent approach to variant detection in conditions
with suspected genetic etiology. In addition to research applications, WES is widely used
in clinical diagnostics.
WES can be applied both on familial and sporadic forms of disease. It is plausible
that a considerable share of sporadic CHD represents de novo variants. This is because
severe CHD reduces reproductive fitness and has a relatively low sibling recurrence risk.
And yet, the incidence of CHD remains constant. WES sequencing of proband-parent
trios is an effective approach to identify de novo variants. Indeed, in an early study, a
marked increase in de novo coding variants in genes highly expressed in a developing
heart was noted in 362 child–parent trios with severe CHD compared to 264 control trios [7].
By filtering out missense mutations, the variants associated with disease increased from
odds ratio (OR) 2.53 to 7.50. More than half of the patients in this study had extracardiac
congenital anomalies, developmental, or growth issues. The de novo variant positivity
was less frequent in patients with isolated CHD, which is in accordance with several later
WES studies showing that damaging de novo variants are significantly more prevalent in
patients with other anomalies and/or neurodevelopmental defects, whereas there is an
excess of inherited damaging mutations in patients with isolated CHD [18,31,32]. Moreover,
an excess of predicted deleterious missense and loss of function de novo variants have
been observed in patients with conotruncal defects, left ventricular outflow tract defects,
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and in patients classified to belong to the “other” category of CHD, but not in patients
with heterotaxy [32] While the genetic basis of CHD is still mostly unsolved, the familial
contribution has been shown to vary between different CHD types and is highest in
heterotaxy, in which, on the other hand, de novo variants are uncommon [7,32–34].
As an aid to interpreting variants in the large WES datasets, Szot et al. [6] curated a
list of 90 high-confidence CHD genes known to cause human CHD when analyzing the
exomes of 30 CHD families and identified a pathogenic variant in 10% of families and a
likely disease-causing variant in 33% of the rest [6]. The list maintained by Victor Chang
Cardiac Research Institute (http://chdgene.victorchang.edu.au, accessed on 5 May 2021)
currently includes 133 genes. In a WES study of patients with left-sided lesions, Li et al. [35]
generated a list of 1760 candidate genes from the literature and model organism databases
identifying a candidate variant in 17 novel and 10 known CHD genes in 14.3% of cases [35].
The yield of variant detection varies widely and depends on the selection criteria of
CHD patients and the stringency of interpretation. Detection of CHD causing variants has
ranged from 2 to 46% [4,5,31,32,36] and is higher in CHD with extracardiac features than
in isolated CHD. It is apparent that a portion of disease-causing variants lie beyond the
exome, suggesting that the increasingly applied whole-genome sequencing (WGS) could
provide additional information. In addition to full coverage of the genome, including
its regulatory sequence, the “regulome”, WGS enables more comprehensive detection of
most types of genomic variation than WES (single nucleotide changes, small insertions and
deletions, and CNVs and some of the structural variation). The pathogenicity of variants
in a non-coding sequence is, however, significantly more difficult to establish than that of
variants in a coding sequence.
The new information WGS has provided to CHD is variable. Reuter et al. analyzed
111 trios or families with a CHD child [37], excluding patients with a designated syndrome
or metabolic disorder. In the cases where still nearly half of the patients had extracardiac
features, a causative variant was identified in 14 families. Eleven patients with diagnostic
variants had extracardiac features, and two had a family history of CHD. By mitigating
the variant interpretation criteria, which were based on American College of Medical
Genetics and Genomics (ACMG) guidelines and evaluation by a clinical geneticist, a
genetic counselor and a cardiologist, to include variants that appeared plausible but did
not meet the criteria for pathogenicity, the number of potentially relevant variants increased
from 14 to 22 without decreasing the proportion of CHD with extracardiac issues. Seven
of the variants were CNVs, two of which included genes with a known contribution to
CHD. Variants involved 17 different genes, two of which were found twice in separate
patients with different cardiac phenotypes. All detected single nucleotide variants (SNV)
were in the coding DNA or in splice sites and therefore could have been detectable also
by WES. Another WGS study of 24 critically ill newborn infants with CHD and other
malformations identified a definitive or likely genetic diagnosis in 11 patients [38]. Some
of the probands were also tested with chromosomal microarray and targeted gene panels
recommended by their primary medical team. Not surprisingly, the diagnostic yield was
higher in WGS. However, excluding a 3 Mb deletion including an established CHD gene,
all variants detected were in coding DNA and could have also been detectable by less
laborious WES. Low read-depth (≈0.6×) WGS has also been successfully used to search
for de novo CNVs in non-syndromic atrioventricular septal defects [39].
Although it is known that in the familial forms, CHD phenotypes can differ be-
tween affected family members [40], it is still more likely that the phenotypes of affected
family members are concordant [2,33]. In addition, variants of certain genes are more
often associated with a certain phenotype, such as NOTCH1 variants with LVOTO de-
fects [2,21,41]. Thus, it is prudent to search for new candidate genes and additional data for
their pathogenicity from the related gene pathways of known disease genes. This approach
was taken in the genome sequencing study of 175 TOF patients in which VEGF-pathway
genes were studied [42], replicating the results of an earlier study indicating that the hap-
loinsufficiency of FLT4 associates with TOF [34]. In addition, KDR loss-of-function variants
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and likely disturbing variants in five other VEGF-pathway genes were identified, strength-
ening the hypothesis of dysregulated VEGF-signaling contributing to the pathogenesis of
TOF [42].
By using complex computational and statistical methods, the evaluation of variants in
non-coding regions has been improved. A WGS study on 763 trios who had not shown
rare damaging missense or loss-of-function coding variants in known CHD genes found
evidence of potentially disruptive regulatory non-coding de novo-variation being at least as
common as a damaging de novo-variation in coding DNA [43]. In this study, 40.8% of the
probands had neurodevelopmental defects and/or extracardiac anomalies. Interestingly,
the findings were similar in probands with isolated CHD and probands with extracardiac
anomalies in contrast to the damaging coding de novo variant enrichment seen among
CHD probands with extracardiac anomalies. Whether variants in non-coding regions are
capable of causing CHD in a Mendelian model remains to be elucidated.
The data analysis in WGS is remarkably more demanding than in WES with a
50–100 fold amount of sequence with deficiently understood biological significance to
be analyzed. Indeed, in many WGS studies, the variants considered disease-causing have
resided in the coding sequence and therefore could have been detected by WES, although
there is data indicating that WGS provides better exome coverage than WES [44]. The true
utilization of WGS is likely to improve in the future with the development of computational
algorithms for the analysis of massive data and with the advancing comprehension of the
function of non-coding DNA.
Reporting candidate variants in CHD studies is still far from delivering the results
to patients in the clinics, as robust evidence for pathogenicity must exist to interpret the
variant as pathogenic. The American College of Medical Genetics and Genomics (ACMG)
has developed a detailed algorithm for the interpretation of sequence variants [45]. For
novel genes without a validated association to a patient’s phenotype, mechanistic data
would be needed before the gene can be classified as a disease gene. This can be done,
for example, by establishing pathogenicity in model animal studies, assaying enzymatic
function directly from biopsied tissue from the patient, or more recently using hiPSCs
based disease models. This is often not possible in the clinical setting. However, while
variant interpretation is cumbersome, the advantage in WES and WGS is that the data can
be re-evaluated or re-analyzed later as new disease-associated variants are being reported.
In diagnostics, often subsets of genes, so-called gene panels, known to be relevant
to the phenotype are analyzed. Commercial gene panels are also offered for CHD [46].
As most of the previously reported pathogenic variants in CHD have been private for
individuals and families, the same difficulties prevail in variant interpretation as in WES
and WGS. Of novel variants, only putative loss of function variants (nonsense, splicing,
or frameshift variants) in genes where haploinsufficiency is not tolerated can be directly
classified as pathogenic or likely pathogenic. Thus, it is likely that the analyses will result
in a high number of variants of uncertain significance (VUS) causing confusion in families.
While gene panels function well for other inherited cardiovascular diseases, such as LQTS
or cardiomyopathies, where the same pathogenic variants recur, their benefit currently is
slim in nsCHD.
4. Genome-Wide Association Studies
As genome-wide sequencing data is becoming available for an increasing number of
populations, a commonly used method of studying the genetic background of traits or
diseases, such as CHD is Genome-wide association studies (GWAS) [47–49]. Generally,
GWASs compare the sequence data, or single nucleotide polymorphism (SNP) array inten-
sities, of cases against controls to determine the effect sizes of genetic variants statistically,
usually SNPs, on the trait in question. To date, there has been a multitude of GWAS studies
on CHD [34,50–55]. However, the generally accepted threshold of genome-wide signifi-
cance for GWASs (p < 5 × 10−8, [56]) has been difficult to achieve, often due to relatively
small case-cohort sizes (usually less than 1000 individuals). This is further complicated by
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the relatively small effect size of common variants on phenotypes in general [57]. Thus,
only a handful of studies have demonstrated genome-wide significant SNPs associated
with CHD (Table 1). As it is known that different CHD lesions have at least partly distinct
genetic etiologies, creating subtype categories of CHD can improve the analysis. For exam-
ple, Lahm et al. [55] demonstrated a significant association of a large cohort of CHD patients
with rs185531658, whereas in the same study, other SNPs showed significant association to
various sub-groups of the cohort; transposition of the great arteries (TGA, six genome-wide
significant variants), right heart lesions (one genome-wide significant variant), left heart
lesions (one genome-wide significant variant), and anomalies of thoracic arteries and veins
(ATAV, one genome-wide significant variant) [55]. Thus, it is important to define CHD
subtypes considered during analysis clearly. The study by Lahm et al. [55] also combined
GWAS data with hiPSC data and human and animal cellular level data to find support for
the results. They showed that the gene with the strongest genome-wide significant SNPs,
MACROD2 (associated with TGA), was expressed during cardiac differentiation of hiPSCs,
in mouse embryonic cardiogenic tissue and during human embryonic development within
ventricular and outflow tract cells [55].
Table 1. Collection of CHD GWAS studies, their significant loci, and nearest genes.
Study Cohorts and CHD Subtype Nearest Genes Significant Loci
Cordell et al., 2013 [52]
835 cases, 5159 controls Tetralogy of Fallot PTPN11 1
Lin et al., 2015 [53]
945 cases, 1246 controls




Agopian et al., 2018 [54]
1940 cases and trios, 2976 controls
Conotruncal heart defect, left
ventricular obstructive tract defect OFCC1 1
Bjornsson et al., 2018 [56]
120 cases, 355,166 controls Coarctation of the aorta MYH6 1
Lahm et al., 2021 [55]
4034 cases, 8486 controls
All CHD phenotypes KCNN2 1
Transposition of the great arteries MACROD2 6
Right heart lesions SLC27A6 1
Left heart lesions ARHGEF4 1
As additional GWASs are performed and the results are added to an already extensive
body of literature, meta-analyses have become a standard approach to integrate data across
different studies of the same trait [58,59]. By combining studies from different consortia,
the sample size and statistical power may be increased. To date, there are multiple meta-
analysis tools available, for example; METAL [59], PLINK [60], GWAMA [61], metafor [62],
and meta [63]. Reports have indicated that meta-analysis provided by meta-analysis soft-
ware is as efficient and powerful as pooling individual-level data across studies but more
convenient and less bulky [59,63]. Furthermore, meta-analysis adds extra layers of analysis,
enhancing the privacy of patients. Current meta-analysis methods also aim to address
concerns regarding the differences in study designs, study cohorts (e.g., environment,
linkage disequilibrium (LD), and ethnic composition), and chip/sequencing platforms
between GWASs of the same trait [58].
5. Human Induced Pluripotent Stem Cells
The method of deriving hiPSCs from adult somatic cells [64], most commonly skin
fibroblasts or peripheral blood mononuclear cells, provides the opportunity to study spe-
cific phenotypes in patient-derived cells [65]. Analyzing the phenotype and transcriptome
of patient-derived hiPSCs that have been differentiated to organotypic cells can pinpoint
specific genes or molecular pathways involved in the disease processes. This approach can
be used for (1) identifying new candidate genes, (2) evaluating the pathogenicity of a new
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candidate disease variant, and (3) exploring the cellular and molecular consequences of a
known disease-causing variant present in the patient (Figure 1).
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Figure 1. Disease modeling with human induced pluripotent stem cells (hiPSC). HiPSCs are derived
from CHD patients and healthy controls. The candidate variant can be corrected with CRISPR-Cas9
technology in patient cells, or it introduced to cells from healthy controls. The hiPSCs can be
differentiated to organo ypic cells, such as cardiomyocytes, endotheli l cells, fibrobla ts, and smooth
muscle cells. The phenotypes of the organotypic hiPSCs with t e candidate variant can be compared
to those without it, and genotype-phenotype associations can be identified. The figure has been
created with BioRender.com.
HiPSC derived cardiomyocytes (hiPS-CM) have been widely used to model cardiomy-
opathies and rhythm di orders, and more ecently, congenital heart defects. Hypoplastic
left heart syndrome (HLHS) i the most commonly studied CHD phenotype [66–69], but
also hiPSCs from patients with NOTCH1-as ociated bicuspid a rtic valve (BAV) [70],
GATA4-associated septal defects, and pulmonary ste osis ([71]), pulmonary atresia with
intact ventricular septum [72], and elastin haploinsufficiency (Wi liams-Beuren syndrome)
related supravalvula aortic tenosis and pulmonary stenosis [73,74] have been studied.
Most studies using HLHS patient-derived hiPSCs have focused on the cardiac myocyte
phenotype in patients with both known or suspected (NOTCH1, MYH6) or unknown
genetic etiology. Common findings from these studies have indicated that HLHS patient-
derived cells have a diminished capacity for cardiomyocyte differentiation which has
been documented on several stages during differentiation and a more immature hiPS-CM
phenotype. The reduced expression of BRACHYURY and ISL1 during differentiation
at day 7 suggests defects in the ability to generate mesodermal and cardiac progenitors,
reduced expression of cTnT, SIRPA, HAND1, and HAND2 at day 14 suggests defects in
generating cardiomyocytes, and the persistent expression of the cardiac progenitor marker
GATA4 and reduced expression of cTnT at day 21 of differentiation indicates an immature
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cell type [67,75,76]. Other commonly reported findings include disorganized sarcomere
structures [66–68,76,77], impaired Notch-signaling [66–68,76], and reduced expression of
cardiac transcription factors, such as NKX2-5 and HAND1 [76] in hiPS-CMs derived from
HLHS subjects. In addition, reduced nitric oxide signaling has been documented in HLHS
hiPS-CMs [68].
All CHD disease phenotypes have not been replicated. For example, the lower
differentiation efficiency of HLHS hiPS-CMs compared to controls is not noted in all
studies [78]. Similarly, a lowered beating rate in HLHS hiPS-CMs [67,77] was not noted
in one study [78]. On the other hand, some of the phenotypic properties shown in HLHS
hiPS-CMs have been detected in hiPS-CMs of other CHD types. Impaired contraction in
patient-derived hiPS-CMs has been reported in not only HLHS-derived hiPS-CMs [67,78]
but also hiPS-CMs from family members with a pathogenic GATA4-variant causing septal
defects and pulmonary stenosis [71], and hiPS-CMs from patients with pulmonary atresia
with intact ventricular septum [72]. It is possible that distinct genetic etiologies contribute
to the differences in phenotypes. It should, however, be kept in mind that phenotypic
differences in the patient-derived hiPS-CMs might also reflect differences in experimental
design and success, as there are many distinct differentiation protocols, and it is well known
that large variations in differentiation efficiency occur [79]. Furthermore, the potential intra-
clonal variation in hiPSC lines should be taken into account [80]. Moreover, it is known
that hiPS-CM protocols can give rise to both atrial and ventricular-like cardiomyocytes,
and protocols to direct the differentiation to each cell type have been established [79,81].
As these two cell types have different transcriptomic and electrophysiological properties, it
is important to know and verify which cell type the used protocols produce. Single-cell
RNA sequencing is a useful tool for investigating differentiation outcomes.
Besides hiPS-CMs, other cell types have also been studied. A recent study using
HLHS-hiPSC-derived endocardial cells and hiPS-CMs indicated that developmentally
impaired endocardium might result in abnormal endocardial to mesenchymal transition
(EndoMT) and angiogenesis leading to ventricular and valvular hypoplasia in HLHS [68].
An impaired endocardial cell population was also detected in human heart tissue of fetuses
with underdeveloped left ventricles. HiPS-derived smooth muscle cells (hiPS-SMCs)
have been used to characterize molecular level mechanisms behind elastin deficiency
causing supravalvular aortic stenosis and pulmonary stenosis. Elastin deficient hiPS-SMCs
demonstrated immaturity with the lowered expression of differentiated SMC markers and
less organized networks of smooth muscle α actin filament bundles [73,74] compared to
hiPS-SMCs from healthy individuals. In addition, they showed increased proliferation and
reduced response to vasoactive agonists [73,74], resembling the phenotype in vivo.
Knowing how variants affect the hiPS-CM phenotype can help in assessing the
pathogenicity of variants of uncertain significance. A recent study demonstrated how
the haploinsufficiency of NAA15, a known CHD gene, perturbs cellular function in hiPS-
CMs. Heterozygous loss of function, compound heterozygous, and missense NAA15
variants were introduced into hiPSCs using CRISPR/Cas9 gene editing, and the conse-
quences of these mutations on hiPS-CM phenotype and RNA and protein expression were
assessed [82]. The study identified four CHD-causing genes (DHCR7, MAP2K2, NSD1,
and RPL5) that were differentially expressed in NAA15 haploinsufficiency, providing
molecular-level mechanisms behind the pathogenicity. Importantly, the study provided a
reference on how to estimate the pathogenicity of NAA15 variants of uncertain significance
in patient-derived cells [82].
Recently more focus has been laid on the genetic determinants of disease course in
CHD patients. For example, myocardial dysfunction is a known complication of HLHS
where the right ventricle (RV) fails in an unexplained manner leading to the need for
heart transplantation. Recent studies have indicated that variants in some cardiomyopathy
genes, such as MYH6, MYBPC3, and RYR2, might predispose for such RV failure [34,83,84].
A recent study using hiPS-CMs from three HLHS subjects with early RV failure during the
first decade of life demonstrated reduced contraction force and contraction acceleration
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compared with hiPS-CMs from healthy controls [78]. Furthermore, the hiPS-CMs had lower
mitochondrial content and reduced oxygen consumption [78]. It was speculated that these
functional impairments might contribute to susceptibility to early failure of the single RV
in patients with HLHS. The study, however, did not analyze hIPS-CMs from HLHS subjects
without RV failure. Thus, this could represent an overall phenotype of HLHS-hIPS-CMs.
Still, this study demonstrates the potential of using hiPS-CMs in estimating disease course
and prognosis.
When using hIPS-CMs for disease modeling, a relevant question is how the pheno-
typic changes in patients and hiPSC-CM disease models align with each other. HiPS-CM
models for diseases, such as Long QT syndrome and hypertrophic and dilated cardiomy-
opathy, where the etiology of the pathologic process is in cardiomyocytes, recapitulate the
electrophysiological, morphologic, and contractile phenotypes observed with the clinical
phenotypes quite well [85]. Whether the hiPS-CM phenotypes resemble those of CHD
patients’ cardiomyocytes in vivo is more difficult to assess. Generally, only little clinical
information about the detailed phenotypes and cell model–patient phenotype correlations
have been obtained from the CHD hiPS-CM studies. Heart development is a complex in-
terplay between several different cell types and signaling pathways, where environmental
factors, such as early blood flow and maternal metabolomics, also play a role [86]. Thus, it
is apparent that a deficiency in cardiomyocytes is not solely, if at all, responsible for the
observed complex phenotypes in CHD. The myocardial RV dysfunction observed in some
HLHS patients can be due to several different causes, such as changes in hemodynamic
stress during the different palliation stages, residual anatomic obstructions, arrhythmias,
valve insufficiencies, myocardial ischemia, and genetic predisposition [87,88]. Thus, a
thorough understanding of the developmental processes as well as of postnatal pathophys-
iological and hemodynamical conditions are essential when drawing conclusions on how
cell models and patient phenotypes correlate in CHD.
Despite the limitations, using hiPSCs in disease modeling has several advantages
compared to animal models. Animal models are more laborious, expensive, and may have
ethical concerns. As patient-derived cells have the original genetic background, modeling
is possible even with unknown or oligogenic etiology. Moreover, while animal models
reflect the in vivo context better than cultured cells, the involved genes, developmental
processes, and disease phenotypes are not always comparable between different species.
Ongoing research on improving the differentiation efficiency and maturation of target cell
types as well as developing cardiac organoids and 3D microtissues, will further enhance
the use of patient-derived hiPSCs in disease modeling.
6. Conclusions
New sequencing technologies and large biobank sample collections have increased
our understanding of the genetic basis of nsCHD. While some monogenic forms of CHD
have been documented, the evidence supporting oligogenic inheritance in the majority of
cases is accumulating. Curated lists of CHD-causing genes ranging from tens to thousands
of genes [5,30] have been established, and even commercial gene panels are available [43].
However, since most of the thus far identified pathogenic variants seem to be specific
to individuals or families, variant interpretation is not trivial. Further, as environmental
exposures and epigenetic regulation contribute to CHD, the benefit of genetic diagnostics
in nsCHD is not clear. Combining sample collections and data from biobanks to achieve
larger patient cohorts and using innovative approaches, such as MR and advanced compu-
tation technologies, to evaluate the effects of common variants could clarify the inheritance
patterns and reveal novel candidate loci. Information on genotype–phenotype associations
from patient-derived organotypic hiPSCs provides an additional asset in evaluating can-
didate variants from WES and GWAS studies. Finally, the identification of gene variants
affecting disease course provides additional impetus for research efforts, as these can guide
disease follow-up and treatment and improve the prognosis of the CHD patient.
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